胎盘组织中胰岛素样生长因子—I的定位及定量分析

目的 探讨胎盘组织中胰岛素样生长因子－Ｉ（ＩＧＦ－Ｉ）定位,评估ＩＧＦ－Ｉ在胎儿生长发育中的作用。方法 用免疫组化法对对妊娠胎盘组织中ＩＧＦ－Ｉ细胞进行定位,并采用计算机医学图像分析系统,检测小于胎龄儿（ＳＧＡ）组２２例,适于胎龄儿（ＡＧＡ）组２５例及大于胎龄儿（ＬＧＡ）组２５例的ＩＧＦ－１,并进行定量分析,用ｔ检验法进行各组间均数检验。结果 （１）胎盘ＩＧＦ－Ｉ主要位于绒毛小叶的合体滋养细胞滋养     

胰岛素样生长因子Ⅰ及胰岛素与胎儿宫内发育迟缓发病的关系

目的 探讨胰岛素样生长因子１（ＩＧＦ－Ｉ）及胰岛素与胎儿宫内发育迟缓（ＩＵＧＲ）发病的关系。方法 应用放射免疫分析法和酶联免疫吸附试验,分别测定１７例ＩＵＧＲ患儿,孕妇（ＩＵＧＲ组）血清及羊水中Ｉｎｓ和ＩＧＦ－Ｉ水平,同期住院的正常晚期妊娠妇女３８例（正常妊娠组）作为对照。     

胰岛素样生长因子I,生长抑素在新生儿缺氧缺血性脑病血液？…

目的 观察胰岛素样生长因子Ｉ（ｉｎｓｕｌｉｎ－ｌｉｋｅ ｇｒｏｗｔｈ ｆａｃｔｏｒ－Ｉ，ＩＧＦ－Ｉ）、生长抑素（ｓｏｍａｔｏｓｔａｔｉｎ，ＳＳ）在新生儿缺氧缺血性脑病（ ｈｙｐｏｘｉｃ－ｉｓｃｈｅｍｉｃ ｅｎｃｅｐｈａｌｏｐａｔｈｙ，ＨＩＥ）极其和恢复期血液中的变化；探讨ＩＧＦ－Ｉ、ＳＳ在ＨＩＥ发病机制中的作用。方法 （１）用放射免疫分析法（ＲＩ）测定正常对照组、ＨＩＥ极期、恢复期血浆ＳＳ的水平。     

胰岛素样生长因子—I与胎儿出生体重的关系

目的 了解胰岛素生长因子－Ｉ（ＩＧＦ－Ｉ）在胎儿生长发育中所起的作用,方法 选择１７１例产妇及其所分娩的新生儿１６４例,根据出生体重将新生儿分为大于胎龄儿（ＬＧＡ）组,产妇７７例,新生儿６４例,适于胎龄儿（ＡＧＡ）组：产妇５９例,新生儿５９例;小儿胎龄儿（ＳＧＡ）组：产妇３５例,新生儿４３例,用放射免疫法测定血清中ＩＧＦ－Ｉ的浓度。结果 母血中ＩＧＦ－Ｉ浓度均高于脐血,两者间存在浓度梯度（Ｐ〈０．     

表皮生长因子与胰岛素对人离体绒毛组织分泌HCS及HCG的影响

目的 观察表皮生长因子（EGF）和胰岛素（insulin)对早期妊娠人工流产的新鲜绒毛组织分泌绒毛膜促生长催乳素（HCS）和绒毛膜促性腺激素（HCG）的影响。方法 选择孕6－10周要求行人工流产术的健康孕妇55例，取其绒毛组织进行灌流。用不同质量浓度的EGF作用于绒毛，同时观察胰岛素及不同质量浓度葡萄糖对绒毛分泌HCS及HCG的影响。用放免方法测定灌洗液中HCS和HCS含量。结果 EGF对早孕绒毛分泌HCS和HCG有双向作用。即：EGF（50μg/L)对HCS和HCG的分泌有明显的促进作用（P＜0．01），而高质量浓度EGF（500μg/L)对其分泌有抑制作用（P＜0．05）。胰岛素可使离体早孕绒毛分泌HCS和HCG有所增加，并证实另一主要影响因素为葡萄糖质量浓度，即：高量浓度葡萄糖（4.0g/L)抑制HCS及HCG分泌（P＜0．05），而低质量浓度葡萄糖（0.4g/L)促进其分泌（P＜0．01）。胰岛素可增强EGF诱导的HCS及HCG分泌（P＜0．001），说明胰岛素可协同EGF的促细胞分化作用，提示胰岛素对胎盘分泌HCS及HCG起重要作用。结论 EGF对HCS及HCG分泌的影响作用是一致的；胰岛素间接使胰岛素样生长因子－I（IGF－I）发挥作用使滋养细胞分泌HCS及HCG增加；胰岛素尚可协同EGF发挥其促细胞分化作用。     

乳腺癌病人的心理护理

乳腺癌是最常见的恶性肿瘤之一，在我国妇女患乳腺癌的发病率占全身恶性肿瘤的7％～10％，并有逐渐上升的趋势，是一种严重危害妇女身体健康的恶性肿瘤，其发病主要与内分泌、遗传、生活饮食习惯、生育、哺乳和癌前期病变有关，其中以内分泌因素较为重要，护理人员在配合医生采取积极治疗措施及护理常规的同时，针对患者心理反应及时采取有效护理，使患者尽快恢复健康。     

婴儿配方奶中胰岛素样生长因子I水平

目的　肠道摄入的胰岛素样生长因子 I(IGF- I)能促进肠粘膜细胞的增殖和增加双糖酶的活性。本研究旨在确定和比较婴儿配方奶、鲜牛奶和人乳的 IGF- I含量。　方法　使用放射免疫分析法测定了 5种水解蛋白质配方奶、5种非水解蛋白质配方奶、2种鲜牛奶和 15份人乳中的 IGF- I水平。　结果　人乳的 IGF- I含量最高 ,为 (0 .6 1± 0 .2 8) nm ol/ L,其次是鲜牛奶为 (0 .2 3± 0 .0 9和 0 .2 7±0 .11) nmol/ L;非水解蛋白质配方奶的含量仅为 (0 .0 8± 0 .0 3)～ (0 .16± 0 .0 1) nmol/ L,而水解蛋白质配方奶的 IGF- I含量在可测范围之下 (<0 .0 2 nmol/ L)。　结论　母乳含丰富的 IGF- I,可能对新生儿和婴儿胃肠道的生长发育有利。婴儿配方奶中的 IGF- I含量明显低于鲜牛奶的 IGF- I含量 ,表明制造配方奶的加工程序 (尤其蛋白质的水解过程 )可破坏 IGF- I结构 ,使其活性和功能丧失。     

局部应用增敏I号增加宫颈癌放疗效果的临床研究

８０例宫颈癌患者在放疗同时局部应用增敏Ｉ号（研究组）与４０例单纯放疗患者（对照组）进行比较研究。结果表明，放疗总有效率研究组为９２．５％，对照组为６２．５％，宫颈局部肿瘤放疗总有效率研究组为９８％，对照组为８０％，两组比较差异有显著性（Ｐ〈０．０５）。     

原癌基因C—myc,C—N—ras,C—Di—ras,C—erbB2在卵巢癌组织中的…

对３２例巢癌、４例卵巢良性上皮性肿瘤、３例卵巢上皮性交界性肿瘤及２例正常卵巢组织进行ＤＮＡＳｏｕｔｈｅｒｎ印迹杂交研究，发现在卵巢癌组织中原癌基因Ｃｍｙｃ，Ｃ－Ｎ－ｒａｓ和Ｃ－Ｋｉ－ｒａｓ，Ｃ－ｅｒｂＢ２扩增率分别为５０％、４４％、３１％、２５％。Ｃ－Ｋｉ－ｒａｓ扩增主要发生在早期和分化好的卵巢癌患者中。Ｃ－Ｎ－ｒａｓ扩增在晚期患者也有表现。Ｃｍｙｃ和Ｃ－ｅｒｂＢ２扩增主要发生在Ⅲ期以上、分化较差     

胰岛素样生长因子及胰岛素样生长因子结合蛋白-3与胎儿生长受限的关系

目的　探讨胰岛素样生长因子 (IGF) Ⅰ、IGF Ⅱ和IGF结合蛋白 3(IGFBP 3)与胎儿生长的关系 ,以及IGF在胎儿生长受限 (FGR)发病中的作用。方法　选取 2 0例分娩FGR胎儿 (FGR组 )、10例分娩巨大儿 (巨大儿组 )及 2 0例分娩正常儿 (对照组 )的产妇 ,抽取 3组产妇分娩后肘静脉血及其新生儿脐静脉血 ,分离血清。采用放射免疫法和免疫放射法测定 3组产妇及其新生儿血清中IGF Ⅰ、IGF Ⅱ及IGFBP 3的水平。结果　 (1)FGR组产妇血清IGF Ⅰ、IGF Ⅱ及IGFBP 3水平分别为(130 5± 2 6 0 ) μg/L、(2 40± 0 42 ) μg/L及(5 5 79± 848) μg/L ;新生儿脐血清IGF Ⅰ、IGF Ⅱ及IGFBP 3水平分别为 (6 6± 1 7) μg/L、(1 5 4± 0 31) μg/L及 (86 9± 183) μg/L。 (2 )巨大儿组产妇血清IGF Ⅰ、IGF Ⅱ及IGFBP 3水平分别为 (30 9 7± 44 6 ) μg/L、(2 43± 0 2 5 ) μg/L及(5 5 6 2± 742 ) μg/L ;新生儿脐血清IGF Ⅰ、IGF Ⅱ及IGFBP 3水平分别为 (6 9 6± 2 3 9) μg/L、(2 19± 0 2 9) μg/L及(16 82± 130 )μg/L。(3)对照组产妇血清IGF Ⅰ、IGF Ⅱ及IGFBP 3水平分别为 (30 7 9± 70 7) μg/L、(2 41± 0 36 )μg/L及 (5 5 86± 6 78) μg/L ;新生儿脐血清IGF Ⅰ、IGF Ⅱ及IGFBP 3水平分别为 (6 8 9     

Ovulation induction increases serum levels of insulin-like growth factor binding protein 1.

The effect of ovulation induction on serum insulin-like growth factor binding protein 1 (IGFBP-1) level in relation to sex hormone binding globulin (SHBG) levels was evaluated. Serum samples were collected 8 to 12 days after ovulation from 26 women undergoing ovulation induction with clomiphene citrate (CC), and from 58 women treated with CC in combination with human menopausal gonadotropin (hMG) and human chorionic gonadotropin (hCG). In addition, serum samples were obtained from 63 spontaneously ovulating women and from 12 women during an anovulatory cycle. Luteal phase serum IGFBP-1 levels were 4.22 +/- 2.95 micrograms/L (P less than .05) in the CC group and 7.31 +/- 6.13 micrograms/L (P less than .001) in the CC/hMG/hCG group as compared to unstimulated ovulatory cycles (2.64 +/- 2.52 micrograms/L). No significant difference in IGFBP-1 levels was seen between spontaneously ovulatory and anovulatory cycles. The serum IGFBP-1 levels correlated positively to SHBG levels (r = .52, P less than .001). The data show that ovulation induction increases serum IGFBP-1 levels in parallel to SHBG levels, indicating that ovarian stimulation, which results in increased steroid hormone production, also induces changes in other factors known to modulate steroid hormone actions.     

Oral contraceptives increase insulin-like growth factor binding protein-1 concentration in women with polycystic ovarian disease.

Insulin-like growth factor-I (IGF-I) stimulates ovarian androgen production. Insulin-like growth factor binding protein-1 (IGFBP-1) inhibits IGF actions in vitro. OBJECTIVE: To investigate the effect of oral contraceptive (OC) pills, given for 3 months, on serum gonadotropin, androgen, IGF-I, and IGFBP-1 concentrations, and glucose tolerance in seven women with polycystic ovarian disease (PCOD) and in five healthy control subjects. PATIENTS: Seven women with PCOD and five healthy control subjects. INTERVENTIONS: An oral glucose tolerance test (OGTT) was performed before and after treatment with OC. RESULTS: After treatment with OC, serum luteinizing hormone, androstenedione, and free testosterone levels decreased, and sex hormone-binding globulin concentration increased in the women with PCOD as well as in the control subjects. The cumulative response of serum insulin to OGTT was larger in the women with PCOD than in the control subjects both before and after treatment. Serum IGF-I concentration, which was unchanged during OGTT, decreased from basal level of 326 +/- 70 micrograms/L to 199 +/- 28 micrograms/L after treatment with OC in the women with PCOD, whereas no change was found in the control subjects (from 235 +/- 11 micrograms/L to 226 +/- 11 micrograms/L). Treatment with OC caused an increase of the mean basal IGFBP-1 concentration from 24 +/- 7 micrograms/L to 73 +/- 14 micrograms/L in the women with PCOD. This increase was constant during the OGTT. In the control subjects, treatment with OC did not result in any significant change in IGFBP-1 concentrations (from 44 +/- 11 micrograms/L to 61 +/- 9 micrograms/L). CONCLUSION: The combination of decreased total IGF-I concentration and increased IGFBP-1 concentration induced by OC may decrease ovarian androgen production in PCOD.     

Serum insulin-like growth factor-I and insulin-like growth factor binding protein-3 in premature rupture of membranes

BACKGROUND: The aim of the study was to evaluate whether the circulating levels of insulin-like growth factor-I (IGF-I) and its major circulating binding protein, IGFBP-3, are affected in premature rupture of membranes (PROM) and preterm delivery. METHODS: The levels of IGF-I and IGFBP-3 were measured in 32 pregnant women with PROM and in 27 healthy gestational age-matched pregnant women. Statistical analyzes were performed by analysis of variance. RESULTS: All the patients with PROM had preterm delivery, at a gestational age of 31.9 +/- 0.4 weeks (mean +/- SEM). In the control subjects, pregnancy proceeded to term. In the PROM patients, the serum IGF-I and IGFBP-3 levels (289 +/- 21 ng/ml and 8248 +/- 407 ng/ml, respectively) were not statistically different from those in the control subjects (275 +/- 22 ng/ml and 7579 +/- 488 ng/ml). Seventeen patients with PROM showed a rise in serum C-reactive protein, indicating subclinical intrauterine infection. Also in this subgroup of patients the levels of serum IGF-I (281 +/- 27 ng/ml) and IGFBP-3 (9010 +/- 633 ng/ml) were not different from those in the control subjects. Before delivery, serial serum samples were available from 22 patients with PROM. No consistent changes in IGF-I or IGFBP-3 concentrations were seen during the mean follow-up period of 9 days. CONCLUSIONS: IGF-I and IGFBP-3 do not appear to play any significant role in the maintenance of pregnancy in PROM patients with preterm delivery, whether or not associated with emerging intrauterine infection.     

The effect of estrogen level on glucose-induced changes in serum insulin-like growth factor binding protein-1 concentration.

OBJECTIVE: To investigate the regulation of insulin-like growth factor binding protein-1 (IGFBP-1) concentration during ovarian stimulation. DESIGN: A prospective study of patients undergoing in vitro fertilization treatment. SETTING: Infertility unit at the University Central Hospital of Oulu, a tertiary referral center. PATIENTS: Sixteen healthy, regularly menstruating lean tubal infertility patients. INTERVENTIONS: Oral glucose tolerance test was performed first in a hypoestrogenic state after suppression by long-term gonadotropin-releasing hormone (GnRH) agonist and, second, in a hyperestrogenic state after stimulation by human menopausal gonadotropins. MAIN OUTCOME MEASURES: Serum concentrations of IGFBP-1, insulin-like growth factor I (IGF-I), insulin and sex hormone-binding globulin were measured before and 2 hours after glucose administration. RESULTS: Before and after glucose administration, the serum IGFBP-1 concentrations were significantly higher in the hyperestrogenic state (estradiol [E2] level 3.5 +/- 0.57 nmol/L) after ovarian stimulation than in the GnRH-analogue-induced hypoestrogenic state before the gonadotropin treatment (E2 level 0.10 +/- 0.02 nmol/L). On both occasions glucose-induced hyperinsulinemia caused a significant decrease in the circulating IGFBP-1 levels, whereas the IGF-I levels remained unchanged. There was a significant correlation between E2 and the insulin-suppressed IGFBP-1 level. The sum of follicular diameters correlated positively with the serum IGFBP-1 concentration. CONCLUSIONS: Gonadotropin-induced hyperestrogenism is related to elevated serum IGFBP-1 levels, either via estrogen-stimulated synthesis or via increased contribution from multiple follicles. Glucose-induced hyperinsulinemia suppresses serum IBFBP-1 concentration equally both in the hypoestrogenic and hyperestrogenic states. Because of similar IGF-I levels, it is likely that the biological activity of IGF-I is different before and after gonadotropin stimulations.     

Lack of insulin-like growth factor binding protein-3 variation after follicle-stimulating hormone stimulation in women with polycystic ovary syndrome undergoing in vitro fertilization.

OBJECTIVE: To investigate serum and follicular fluid (FF) insulin-like growth factor-I (IGF-I) and insulin-like growth factor binding protein-3 (IGFBP-3) behavior in superstimulated cycles in patients with polycystic ovary syndrome (PCOS). DESIGN: Controlled clinical study. SETTING: Department of Obstetrics and Gynecology, University of Naples. PATIENT(S): Thirty-two patients with regular menses and tubal and/or male factor infertility and 21 patients with PCOS undergoing IVF. INTERVENTION(S): The IVF program used leuprolide acetate suppression followed by sequential hMG in the subsequent cycle. After follicular development, hCG administration was followed 34-36 hours later by oocyte retrieval. MAIN OUTCOME MEASURE(S): E2, GH, IGF-I, and IGFBP-3 assayed by RIA and immunoradiometric assay. RESULT(S): The controls and patients with PCOS showed similar increases in E2 and GH titers in response to FSH stimulation. Serum IGF-I did not change in either group and was equivalent in the FF. Patients with PCOS had a higher FF IGFBP-3 titer and did not show the decrease in serum IGFBP-3 levels of the control group after FSH stimulation. CONCLUSION(S): The apparent failure of IGFBP-3 reduction in patients with PCOS alters IGF-I bioavailability. Increased sequestration of IGF-I affects ovarian steroidogenesis and may explain the poor response to gonadotropin stimulation.     

Serum insulin-like growth factor binding protein-1 at 16 weeks and subsequent preeclampsia

OBJECTIVE: To determine whether serum concentrations of insulin-like growth factor-binding protein-1 (IGFBP-1), a major decidual protein, at 16 weeks' gestation differ between women who later develop pregnancy-related hypertension and normotensive women. METHODS: Concentrations of IGFBP-1 were measured using immunoenzymometric assay in serum samples collected for alpha-fetoprotein (AFP) and free beta subunit of hCG (free beta-hCG) determinations in a Down syndrome screening program at 16 weeks' gestation in a population-based cohort of 1049 nulliparous women. After exclusion of subjects with multiple pregnancies, insulin-dependent diabetes, major fetal malformations, and incomplete data, 917 subjects remained eligible. RESULTS: The mean levels (+/- standard deviation) of IGFBP-1 were significantly lower in 34 women who later developed preeclampsia (73 +/- 43 microg/L, P < .01) and in 80 women with White A diabetes (84.7 +/- 53 microg/L, P < .01) compared with controls (103 +/- 58 microg/L). In seven women with White A diabetes and subsequent preeclampsia IGFBP-1 levels were especially low (41 +/- 34 microg/L). The concentrations of AFP and free beta-hCG in the subgroups with hypertensive disorders were not significantly different from those of normotensive women. CONCLUSION: Decreased IGFBP-1 levels at 16 weeks' gestation in women who develop preeclampsia might indicate impaired decidual function. Hyperinsulinemia, a known risk factor for preeclampsia, might contribute to decreased concentrations of serum IGFBP-1. However, due to low sensitivity, assay of serum IGFBP-1 was not clinically valuable for predicting preeclampsia.     

胰岛素样生长因子1及胰岛素样生长因子结合蛋白3与胎儿生长发育的关系

目的:探讨胰岛素样生长因子1（IGF-1）及胰岛素样生长因子结合蛋白3（IGFBP-3）与胎儿生长发育的关系。方法:应用酶联免疫吸附试验（LISA）测定26例正常妊娠（正常组）,42例妊娠期糖尿病（GDM组）,20例胎儿宫内发育迟缓（IUGR组）孕妇足月剖宫产分娩时,母血与脐血中IGF-1及IGFBP-3的水平,同时记录3组孕妇的新生儿出生体重。结果:（1）母血IGF-1及IGFBP-3的水平正常组分别为18 6.81μg/L、22.82μg/L,GDM组为283.35μg/L、28.29μg/L,IUGR组为220.64μg/L、25.23μg/L,3组间 IGF-IN IGFBP.3水平差异均无显著性（P>0.05）;（2）脐血IGF-1及IGFBP-3的水平正常组分别为62.54μg/L、8.56μg/L,GDM组分别为83.74μg/L、10.21μg/L,IUGR组为37.94μg/L、7.82μg/L,分别进行3组间两两比较,3组IGF-1及IGFBP-3的差异均有显著性（P<0.01）;（3）新生儿平均出生体重正常组为3.22±0.32kg,GDM组为3.76±0.43kg,IUGR组为2.41±0.17kg,3组间两两比较,差异均有显著性（P<0.01）;（4）3组脐血IGF-1及IGFBP-3水平与新生儿出生体重均有显著性正相关（P<0.01）;（5）3组母血及脐血的IGF-1与IGFBP-3均呈显著性正相关（P<0.01）。结论:来自胎儿循环的IGF-1、IGFBP-3对胎儿的生长发育有重要的调节作用,可能参与巨大儿及IUGR的病     

Decreased 34K insulin-like growth factor binding protein in polycystic ovarian disease

Insulin and insulin-like growth factor I (IGF-I) have been implicated in ovarian androgen production. Insulin is closely related to IGF-I and cross-reacts with its receptor. The 34K IGF-binding protein (34K IGF-BP) has been shown to inhibit the binding of IGF-I to its receptor. The authors evaluated the role of insulin in the regulation of serum levels of 34K IGF-BP in patients with polycystic ovarian disease (PCOD). 34K IGF-BP levels during an oral glucose tolerance test (OGTT) were measured in 15 PCOD (8 obese and 7 nonobese) patients and in 10 healthy control subjects. The fasting level of 34K IGF-BP was decreased in nonobese PCOD patients (2.4 +/- 0.3 micrograms/l) (mean +/- standard error) (P = 0.02) and obese PCOD patients (0.59 +/- 0.2 micrograms/l) (P less than 0.001) as compared with healthy controls (4.8 +/- 0.9 micrograms/l). Both nonobese PCOD patients and normal controls demonstrated a significant decrease in 34K IGF-BP following OGTT. An insulin-related decrease in 34K IGF-BP may allow an increased pool of IGF-I able to bind to its receptor. This would provide a mechanism for increased ovarian androgen production via IGF-I stimulation of its receptor.